1 not yet recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Not yet recruiting 1 |
Follow this condition Literature Review of HR Positive, HER2 Positive Breast Cancer trials Research Report on HR Positive, HER2 Positive Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer Culmerciclib, Letrozole, Trastuzumab (TQB211) - Breast Cancer, HR Positive, HER2 Positive Breast Cancer | Phase 2 | Not yet recruiting | Shengjing Hospital | 33 | 2026-09-01 | 2026-08-31 |
Breast Neoplasms (1)
Breast Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Letrozole (1) · Trastuzumab (1) · pertuzumab (1)
China (1)